All Insights White Paper Pharma Sales And Marketing Restrictions – Has The Pendulum Swung Too Far?

    Pharma Sales And Marketing Restrictions – Has The Pendulum Swung Too Far?

    Sales Operations

    Pharma Sales And Marketing Restrictions – Has The Pendulum Swung Too Far?

    The question this commentary asks is - Has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices?

    Pharma Sales And Marketing Restrictions – Has The Pendulum Swung Too Far?

    The question this commentary asks is simply this - has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceutical companies to the point that they now may well stifle the very innovative environment needed by companies to meet the scientific demands and expectations of society? The answer to this question leads to understanding how and what empirical evidence should the industry generate in response to critics to demonstrate the effects of potentially excessive regulation of the industry.

    Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.

    Contact us at insights@axtria.com for any questions.

    Complete the brief form to download the white paper

    Recommended insights

    Pharma Sales And Marketing Restrictions

    Blog

    Why Emerging Pharma Companies Move Away From Point-Solutions? – Part 2

    Pharma Sales And Marketing Restrictions

    Blog

    Top Life Sciences AI Content for the Self-Quarantined Geek

    Pharma Sales And Marketing Restrictions

    Blog

    A Roadmap for Establishing and Maturing Omnichannel Marketing Within Life Sciences